| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 8.715 | 10.753 | 7.347 | 8.218 |
| Total Income - EUR | - | - | - | - | - | - | 8.715 | 10.753 | 7.347 | 8.218 |
| Total Expenses - EUR | - | - | - | - | - | - | 1.538 | 7.266 | 5.862 | 5.567 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 7.177 | 3.488 | 1.486 | 2.652 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 6.961 | 3.348 | 1.249 | 2.291 |
| Employees | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Medoxand S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 1.509 | 1.149 | 781 | 432 |
| Current Assets | - | - | - | - | - | - | 5.548 | 9.282 | 2.842 | 3.196 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 332 | 255 |
| Receivables | - | - | - | - | - | - | 0 | 4.965 | 485 | 493 |
| Cash | - | - | - | - | - | - | 5.548 | 4.317 | 2.025 | 2.449 |
| Shareholders Funds | - | - | - | - | - | - | 7.001 | 10.371 | 1.297 | 3.582 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 56 | 59 | 2.326 | 47 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9319 - 9319" | |||||||||
| CAEN Financial Year |
9319
|
|||||||||
Comments - Medoxand S.r.l.